

1  
2 **IMMUNE PROFILES TO DISTINGUISH HOSPITALIZED VERSUS AMBULATORY COVID-**  
3 **19 CASES IN OLDER PATIENTS**  
4

5 Jérôme Klingler<sup>1,2</sup>, Gregory S. Lambert<sup>1</sup>, Juan C. Bandres<sup>1,2</sup>, Rozita Emami-Gorizi<sup>2</sup>, Arthur Nádas<sup>3</sup>,  
6 Kasopefoluwa Y. Oguntuyo<sup>4</sup>, Fatima Amanat<sup>4,5</sup>, PARIS Study Team<sup>4,6</sup>, Viviana Simon<sup>1,4,6,7,8</sup>, Benhur  
7 Lee<sup>4</sup>, Susan Zolla-Pazner<sup>1,4</sup>, Chitra Upadhyay<sup>1</sup>, Catarina E. Hioe<sup>1,2,4\*</sup>

8 <sup>1</sup>Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New  
9 York, NY, USA

10 <sup>2</sup>James J. Peters VA Medical Center, Bronx, NY, USA

11 <sup>3</sup>Department of Environment Medicine, NYU School of Medicine, New York, NY, USA

12 <sup>4</sup>Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA

13 <sup>5</sup>Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY,  
14 USA

15 <sup>6</sup>Department of Pathology, Molecular and Cell Based Medicine, Icahn School of Medicine at Mount Sinai,  
16 New York, NY, USA

17 <sup>7</sup>Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York,  
18 NY, USA

19 <sup>8</sup>Center for Vaccine Research and Pandemic Preparedness, Icahn School of Medicine at Mount Sinai, New  
20 York, NY, USA

21  
22  
23 \*Co-corresponding author

24 Contact: [catarina.hioe@mssm.edu](mailto:catarina.hioe@mssm.edu), [catarina.hioe@va.gov](mailto:catarina.hioe@va.gov)

25  
26 **Abstract**

27 **Background:** A fraction of COVID-19 patients develops severe disease requiring hospitalization, while  
28 the majority, including high-risk individuals, experience mild symptoms. Severe disease has been  
29 associated with higher levels of antibodies and inflammatory cytokines, but the association has often  
30 resulted from comparison of patients with diverse demographics and comorbidity status. This study

31 examined patients with defined demographic risk factors for severe COVID-19 who developed mild vs.  
32 severe COVID-19.

33 **Methods:** This study evaluated hospitalized vs. ambulatory COVID-19 patients in the James J. Peters VA  
34 Medical Center, Bronx, NY. This cohort presented demographic risk factors for severe COVID-19:  
35 median age of 63, >80% male, >85% black and/or Hispanic. Sera were collected four to 243 days after  
36 symptom onset and evaluated for binding and functional antibodies as well as 48 cytokines/chemokines.

37 **Findings:** Ambulatory and hospitalized patients showed no difference in SARS-CoV-2-specific antibody  
38 levels and functions. However, a strong correlation between anti-S2 antibody levels and the other antibody  
39 parameters was observed in hospitalized but not in ambulatory cases. Cytokine/chemokine levels also  
40 revealed differences, with notably higher IL-27 levels in hospitalized patients. Hence, among the older,  
41 mostly male patients studied here, SARS-CoV-2-specific antibody levels and functions did not distinguish  
42 hospitalized and ambulatory cases but a discordance in S2-specific antibody responses was noted in  
43 ambulatory patients, and elevated levels of specific cytokines were maintained in convalescent sera of  
44 hospitalized cases.

45 **Interpretation:** The data indicate that antibodies against the relatively conserved S2 spike subunit and  
46 immunoregulatory cytokines such as IL-27 are potential immune determinants of COVID-19.

47

## 48 **Keywords**

49 SARS-CoV-2, COVID-19, high-risk population, antibodies, cytokines, IL-27

50

## 51 **Research in context**

52 **Evidence before this study:** Previous studies demonstrated that high levels of SARS-CoV-2 spike  
53 binding antibodies and neutralizing antibodies were associated with COVID-19 disease severity.

54 However, the comparisons were often made without considering demographics and comorbidities.

55 Correlation was similarly shown between severe disease and marked elevation of several plasma cytokines  
56 but again, most analyses of cytokine responses to COVID-19 were conducted by comparison of patient  
57 cohorts with diverse demographic characteristics and risk factors.

58 **Added value of this study:** We evaluated here a comprehensive profile of SARS-CoV-2-specific  
59 antibodies (total Ig, isotypes/subtypes, Fab- and Fc-mediated functions) and a panel of 48 cytokines and  
60 chemokines in serum samples from a cohort of SARS-CoV-2-infected patients with demographic risk  
61 factors for severe COVID-19: 81% were male, 79% were >50 years old (median of 63), and 85%  
62 belonged to US minority groups (black and/or Hispanic). Comparison of hospitalized vs. ambulatory  
63 patients within this cohort revealed two features that differed between severe vs. mild COVID-19 cases: a  
64 discordant Ab response to the S2 subunit of the viral spike protein in the mild cases and an elevated  
65 response of specific cytokines and chemokines, notably IL-27, in the severe cases.

66 **Implications of all the available evidence:** Data from the study identified key immunologic markers for  
67 severe vs. mild COVID-19 that provide a path forward for investigations of their roles in minimizing or  
68 augmenting disease severity.

69

## 70 **Background**

71 The emergence and rapid spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in  
72 Wuhan, China, in December 2019 has led to a pandemic that continues to impact people worldwide.

73 While research about this virus has progressed rapidly, leading to expeditious development of many types  
74 of diagnostic tests, treatments, and vaccines, important questions remain about the dynamic virus-host  
75 interactions that result in a wide range of disparate disease outcomes.

76 Coronavirus disease 2019 (COVID-19), the disease caused by SARS-CoV-2, can occur with different  
77 clinical manifestations. During the initial outbreak in China, most patients presented with mild to  
78 moderate symptoms which resolved without medical interventions, but ~15% of patients progressed  
79 rapidly to severe disease requiring hospitalization (1,2). Among the hospitalized, patients also require  
80 different levels of intervention. Around a third of hospitalized patients developed acute respiratory disease  
81 syndrome (ARDS) and require mechanical ventilation (3). Elderly patients and individuals with  
82 comorbidities, such as cardiovascular disease, diabetes mellitus, chronic lung disease, chronic kidney  
83 disease, obesity, hypertension, and cancer, have a much higher mortality rate than healthy younger adults  
84 (4). In addition, the overall COVID-19 case-fatality ratio is at least 2.4 times higher in men than in women  
85 (5–7).

86 Understanding the immune responses associated with disease severity and recovery is essential to develop  
87 and apply effective treatments against COVID-19. While high levels of binding antibodies (Abs), in  
88 particular IgA, and neutralizing Abs have been associated with disease severity (8–10), comparison of  
89 severe and mild cases was often without consideration for age, sex, and comorbidities. Indeed, a study of  
90 infected patients from a wide range of age groups (1-102 years) demonstrated that anti-SARS-CoV-2 Ab  
91 levels varied depending on age (11). The levels in the 1-10 years old group were around three- to four-fold  
92 higher than the 25-102 years old groups. Another study comparing SARS-CoV-2-infected male and  
93 female patients from diverse ethnic groups showed no difference in Ab titers (12). However, male patients

94 had higher plasma levels of innate immune cytokines and more robust induction of non-classical  
95 monocytes, while female patients developed significantly more robust T cell activation (12). IgG Fc  
96 glycome composition was also shown to predict disease severity but comparison was within a patient  
97 cohort that included both sexes and had an age range of 21 to 100 years old (13).

98 In addition to Abs, cytokine responses in severe vs. mild COVID-19 cases have been evaluated. An  
99 association was shown between SARS-CoV-2 infection and marked elevation of several plasma cytokines  
100 including interferon gamma-induced protein 10 (IP-10), chemokine (C-X-C motif) ligand 16 (CXCL16),  
101 interleukin (IL)-1 $\beta$ , IL-2R, IL-4, IL-6, IL-8, IL-10 and IL-17 (10,14–21). Several other studies provided  
102 evidence that type I interferon deficiency may lead to severe COVID-19, implying that disease severity  
103 may be due to impaired viral clearance and uncontrolled viral replication due to poor induction of early  
104 innate immunity (15,22–26). Another study revealed a positive association of the illness duration in severe  
105 cases with levels of IL-8 and soluble IL-2R $\alpha$  (27). Further, a longitudinal study on 40 hospitalized  
106 COVID-19 patients found 22 cytokines that were correlated with disease severity (28). Yet, in a study  
107 looking at cytokine and leukocyte profile of COVID-19 patients >60 vs. <60 years old, another set of  
108 cytokines/chemokines was found to correlate with older age, longer hospitalization, and a more severe  
109 form of the disease (29). Similar to the Ab studies, most analyses of cytokine responses to COVID-19  
110 were conducted by comparison of patient cohorts with diverse demographics and risk factors.

111 Further investigations of Ab and cytokine responses to SARS-CoV-2 among racial/ethnic minority US  
112 populations at risk of developing severe COVID-19 are warranted. Indeed, a study among US veterans  
113 showed that black and Hispanic individuals have experienced an excess burden of SARS-CoV-2 infection  
114 that was not entirely explained by underlying medical conditions or where they lived or received care (30).  
115 Immune responses to vaccinations also are influenced by host genetic and demographic variables such as  
116 race, ethnicity, and sex, as demonstrated by induction of higher neutralizing Ab titers following rubella  
117 vaccination in individuals of African descent as compared to the European and Hispanic subjects,

118 although the cytokine responses were comparable (31).

119 Here, we evaluated SARS-CoV-2-specific (spike, RBD, S1, S2, nucleoprotein) Ab responses and  
120 conducted multiplex analysis of cytokines and chemokines in a cohort with risk factors for severe  
121 COVID-19. Of the 52 VA subjects from James J. Peters VA Medical Center (JJP VAMC), 81% were  
122 male, 79% were >50 years old (median 63), and 85% belonged to US minority groups (black and/or  
123 Hispanic). All were infected with SARS-CoV-2, as confirmed by diagnostic RT-PCR, during April-  
124 November 2020. Convalescent serum samples collected four to 243 days post disease onset were studied.  
125 We compared different categories of COVID-19 patients within this VA cohort: ambulatory (n=42) vs.  
126 hospitalized (n=10) patients, COVID-19 patients with (n=24) vs. without (n=28) comorbidities. We also  
127 compared a subset of specimens (n=20) from hospitalized vs. ambulatory cases that were matched based  
128 on sex, time post-infection, comorbidities, and spike-specific Ig levels. In addition, pre-pandemic and  
129 contemporaneous COVID-19-negative samples were studied. The data demonstrate that, in this cohort of  
130 older and mostly male VA patients, hospitalized and ambulatory patients had comparable binding and  
131 functional Abs, but diverged in their responses to the S2 spike subunit. Moreover, heightened levels of  
132 certain cytokines were detected and maintained in convalescent sera from hospitalized vs. ambulatory  
133 cases.

134

## 135 **Methods**

136 **Recombinant proteins.** SARS-CoV-2 spike (full-length external region, amino acids 1-1213) and RBD  
137 (amino acids 319-541) proteins were produced as described before (32,33). S1 (amino acids 16-685), S2  
138 (amino acids 686-1213), and nucleoprotein (amino acids 1-419) antigens were purchased from ProSci Inc,  
139 CA (catalog #97-087, #97-079 and #97-085, respectively). All antigens were of SARS-CoV-2 Wuhan-Hu-  
140 1 (WA1) strain.

141 **Human samples.** Fifty-two COVID-19-convalescent sera samples and 49 COVID-19-negative samples  
142 (38 contemporaneous and 11 pre-pandemic) were collected at JJP VAMC under IRB#BAN-1604 and the  
143 JJP VAMC Quality Improvement project “Evaluation of the clinical significance of two COVID-19  
144 serologic assays”. In addition, five SARS-CoV-2 seronegative serum samples were sourced from the  
145 PARIS cohort, which follows health care workers since March 2020 (IRB-20-03374, approved by the  
146 Mount Sinai Hospital Institutional Review Board). All participants in the PARIS cohort and other research  
147 protocols provided written informed consent and agreed to future research and sample sharing. Samples  
148 were coded prior to processing, testing, and sharing. Of the COVID-19-negative specimens, 21 were used  
149 in the Ab binding and activities experiments, and 28 were used for the cytokines induction experiments.  
150 Before use, all sera were heat-inactivated (30 min at 56 °C, for Ab binding and activities experiments) or  
151 treated with 1% Triton X-100 (30 min at room temperature, for the cytokines induction experiments).

152 **Ab binding assay.** The initial Ab evaluation was done on the Abbott Architect instrument using the  
153 Abbott SARS-CoV-2 IgG assay, a chemiluminescent microparticle immunoassay to detect IgG against the  
154 virus nucleoprotein. Subsequent Ab analyses were performed using the multiplex bead Luminex platform,  
155 in which recombinant SARS-CoV-2 spike, RBD, S1, S2, and nucleoprotein antigens were coupled to  
156 beads and experiments performed as described in (34,35).

157 **Neutralization.** SARS-CoV-2 pseudotyped particles (COV2pp) with spike protein of WA1 strain were  
158 produced and used in neutralization assays as described before (36–38).

159 **ADCP.** Assays to measure spike-specific ADCP were performed using a published protocol (39) with  
160 some modifications reported elsewhere (35).

161 **Cytokines induction.** The samples were tested for 48 cytokines/chemokines by Eve Technologies  
162 Corporation, Canada (Human Cytokine/Chemokine 48-Plex Discovery Assay® Array (HD48)). Data were  
163 presented as concentrations (pg/mL) or modified Z scores. The modified Z scores used to normalize the  
164 data were calculated as:

$$\text{Modified } Z \text{ score} = \frac{0.6745 * (\text{Single data value} - \text{Median of the dataset})}{\text{Median absolute deviation of the dataset}}$$

**Statistical analysis.** Statistical analyses were performed as designated in the figure legends using GraphPad Prism 9 (GraphPad Software, San Diego, CA).

**Role of the funding source.** The study sponsors had no involvement in study design, data collection, analysis, and interpretation, manuscript writing, and decision to submit the paper for publication.

## Results

### **Ab responses to different SARS-CoV-2 antigens among hospitalized and ambulatory VA patients.**

Fifty-two COVID-19-convalescent (**Table 1**) and 21 COVID-19-negative serum samples were collected from a cohort of patients who received care at the JJP VAMC. Samples were collected between March and December 2020, during the first year of COVID-19 pandemic in New York City. COVID-19 diagnosis was confirmed by positive PCR test. The vast majority of the COVID-19-convalescent subjects was male (80%), Black/Hispanic (85%), and >50 years old (79%, median=63, Q1-Q3=52-74), which are representative demographics of the US Veterans population. The preponderance for male and older age in this cohort allowed for characterization of immune responses in the population known to be at risk for severe COVID-19. The COVID-19 patients were categorized in two groups: hospitalized (n=10) vs. ambulatory (n=42). No difference in age and race/ethnicity was observed between the hospitalized vs. ambulatory patients (**Fig 1a**). However, all the hospitalized patients were male, while 10 of the 42 ambulatory patients were female. Analyses also considered the presence or absence of comorbidities known to be associated with more severe COVID-19, which included HIV, obesity, chronic obstructive pulmonary disease, diabetes, asthma, end stage renal disease or pulmonary embolism.

Longitudinal specimens of the COVID-19 patients were initially tested for SARS-CoV-2 nucleoprotein-specific IgG (**Fig 1b**). These COVID-19 patients generated IgG responses against nucleoprotein, which



188 peaked around day 75 post-infection. The responses declined subsequently, but the Abs were detected  
189 above cut-off up to 250 days post-infection in all except for two ambulatory patients. Samples from these  
190 two patients, collected at day 27 and day 214 post-infection, although negative for nucleoprotein-specific  
191 IgG (**Fig 1b**), were positive for spike-specific IgM and IgG, respectively (data not shown) and were both  
192 positive for total Ig against spike and nucleoprotein (**Fig 1c**). Of note, the anti-nucleoprotein IgG levels  
193 among hospitalized patients overlapped with those of ambulatory patients, and no difference was apparent  
194 in the peak levels and the decline rates between the two groups (**Fig 1b**). There was also no apparent  
195 clustering of patients with vs. without comorbidities (**Fig. 1b**).

196 The specimens collected at the last time point from each subject were available for further investigation.  
197 The time points ranged from 4-243 days after symptom onset, with median of 178 and 188 days for  
198 hospitalized and ambulatory group, respectively (**Fig 1a**). To examine the relative levels of Abs induced  
199 by hospitalized vs. ambulatory patients against spike and its domains as compared to nucleoprotein, the  
200 serum samples were titrated for total Ig against spike, RBD, S1, S2 and nucleoprotein antigens (**Fig 1c-e**  
201 **and Supplemental Fig 1**). COVID-19 patients induced highly variable levels of Abs against each of the  
202 five antigens tested, but all displayed Ig reactivity above cut-off (calculated as mean + three standard  
203 deviations (SD) of five COVID-19-negative specimens) (**Fig 1c and Supplemental Fig 1a**). The S2-  
204 specific Ab levels were relatively low (**Supplemental Fig 1a**), similar to past reports on other cohorts of  
205 infected and vaccinated subjects (36). There was a trend of higher median levels of Abs against all five  
206 antigens in the hospitalized group as compared to the ambulatory group, but the differences did not reach  
207 statistical significance and the individual Ab levels from the two groups essentially overlapped (**Fig 1c**  
208 **and Supplemental Fig 1a**), indicating that the two groups of patients could not be differentiated by their  
209 anti-SARS-CoV-2 Ab levels. Moreover, there was no difference in the Ab levels of patients with vs.  
210 without comorbidities (**Fig 1d and Supplemental Fig 1b**).

211 Because the sample collection times were over a wide range of days after disease onset, we searched for  
212 changes in total Ig levels against each of the five SARS-CoV-2 antigens over time after disease onset (**Fig**  
213 **1e and Supplemental Fig 1c**). The Ig responses to spike did not decline over the 250 days post-onset  
214 (slope=56.7 and p=0.71) (**Fig 1e**). Ig levels against RBD and S1 also did not decrease over this period,  
215 while the S2- and nucleoprotein-specific Ig levels demonstrated a non-significant decline (**Supplemental**  
216 **Fig 1c**). Interestingly, when the specimens were divided according to the disease severity, the S2-specific  
217 Ig levels overtime showed a trend of positive slope for the hospitalized patients and negative slope for the  
218 ambulatory patients (**Fig 1f**). This pattern was not seen with Abs against S1 or RBD (data not shown).

219  
220 **Neutralization activities against SARS-CoV-2 among hospitalized and ambulatory VA patients.**  
221 COVID-19-convalescent sera were tested for neutralization activities against SARS-CoV-2 using a  
222 pseudovirus bearing SARS-CoV-2 spike protein (WA1 strain) as performed previously (36–38). COVID-  
223 19-negative sera (n=21) were tested in parallel as control. Samples from all COVID-19-positive patients  
224 had neutralization activity reaching readily above 50%, while none of the COVID-19-negative sera did ( $IC_{50}$   
225 <10) (**Fig 2**). Neutralization titers of hospitalized and ambulatory patients did not differ, although the sample  
226 size of the hospitalized group was small (n=10). The  $IC_{50}$  values ranged from 60 to 3313 for hospitalized  
227 patients (median=194) and from 43 to 4402 for ambulatory patients (median=162.5). Neutralization titers  
228 were also similar between groups with vs. without comorbidities associated with severe COVID-19 (**Fig**  
229 **2b**). In addition, the neutralization titers showed no association with age (**Fig 2c**) and no decline with time  
230 (**Fig 2d**), demonstrating that these parameters do not influence SARS-CoV-2-neutralizing titers detected in  
231 sera of this VA cohort.

232  
233 **Isotypes of serum Abs against SARS-CoV-2 spike produced by hospitalized and ambulatory**  
234 **patients.** To understand the Fc properties of Abs raised against SARS-CoV-2 in patients presenting with

235 distinct COVID-19 severity, we examined spike-specific Ig isotypes in a subset of hospitalized (n=6) vs.  
236 ambulatory cases (n=14) in which each hospitalized patient was matched to two or three ambulatory  
237 patients based on sex, time post-infection (early: <25 days vs. late: >130 days post-infection),  
238 comorbidities (none vs. at least one), and spike-specific total Ig levels (< half a log<sub>10</sub>) (**Table 2**). Four  
239 COVID-19-negative plasma specimens were included to establish background levels. All the patients had  
240 IgM, IgG1, IgG3 and IgA1 spike-specific Abs. The levels of these isotypes and subtypes did not differ  
241 between the hospitalized and ambulatory groups (**Fig 3**). Similar results were observed with Ig isotypes  
242 against RBD (**Supplemental Fig 2**). Some patients also mounted IgG2 and IgG4 Ab responses. The levels  
243 of these IgG subtypes were relatively low, and no difference was apparent between matched hospitalized  
244 and ambulatory patients. These data demonstrate that hospitalized and ambulatory patients display a  
245 comparable array of serum Ig isotypes against SARS-CoV-2 spike and RBD.

246

247 **Fab-mediated neutralization and Fc-mediated activities of SARS-CoV-2-specific Abs among**  
248 **matched hospitalized and ambulatory VA patients.** The matched set of hospitalized and ambulatory  
249 specimens was next tested for Ab activities against SARS-CoV-2. In addition to Fab-mediated  
250 neutralization, we examined Fc-mediated activities: spike-specific ADCP and spike- or RBD-complement  
251 binding (C1q and C3d) (**Fig 4 and Supplemental Fig 3**). Similar to the neutralization data shown in **Fig 2**  
252 for all samples, neutralization levels between matched hospitalized (median IC<sub>50</sub> of 175) and ambulatory  
253 (median IC<sub>50</sub> of 142) specimens were not different (**Fig 4a**). While certain hospitalized patients displayed  
254 higher IC<sub>50</sub> than their matched ambulatory counterparts, some others had lower IC<sub>50</sub> values. Fc-mediated  
255 spike-specific ADCP also showed no apparent trend, and the levels were indistinguishable between  
256 hospitalized and ambulatory groups (median AUC of 518 and 485, respectively) (**Fig 4b**). When  
257 complement binding and activation were examined, the capacity of spike- and RBD-specific Abs for C1q  
258 binding was found to be similar for both groups, and the C3d deposition levels also did not differ (**Fig 4c-**

259 **d and Supplemental Fig 3).**

260 Correlation matrix was compiled from both binding and functional Ab data of the hospitalized and  
261 matched ambulatory groups. A remarkable difference was noted: in the hospitalized group, a strong  
262 positive correlation was observed between the levels of S2-specific Ig and the other Ab parameters tested,  
263 whereas the correlation was weaker or absent in the ambulatory group (**Fig 5a-b**). Indeed, in the  
264 ambulatory group, poor correlation was apparent between the anti-S2 Ig levels and the Ig levels against  
265 the entire spike protein, S1, or RBD (**Fig 5b**). These results indicate a discordance of Ab responses against  
266 the relatively conserved S2 subunit vs. the rest of spike regions in the ambulatory cases but not the  
267 hospitalized cases.

268

269 **Differences in cytokines responses among hospitalized and ambulatory patients.** In addition to  
270 evaluating the Ab responses, we examined the cytokines profile of these convalescent COVID-19 patients.  
271 Fifty-two COVID-19-convalescent patients and 28 COVID-19 negative sera were tested for 48 cytokines  
272 and chemokines, many of which participate in induction and modulation of inflammatory responses (**Figs**  
273 **6 and 7, Supplemental Figs 4-7**). Twelve cytokines/chemokines were found to be significantly different  
274 between COVID-19-positive and negative groups (**Fig 6a, Supplemental Fig 4**). MDC and RANTES  
275 were significantly higher in COVID-19 convalescent sera than negative controls, while the remaining 10  
276 were lower in COVID-19 convalescent sera, with sCD40L and IL-17E/IL-25 displaying p values of  
277  $<0.0001$ . Linear regression analysis of these 12 cytokines showed that the cytokine levels did not change  
278 significantly up to 250 days after COVID-19 disease onset (**Supplemental Fig 5**), except for IL-15 and  
279 M-CSF which declined over time (slope=  $-0.001$  and  $-0.002$ , and  $p=0.02$  and  $0.007$ ).

280 We subsequently compared COVID-19 patients with different disease severity and asked whether the  
281 cytokines/chemokine responses were elevated in hospitalized patients compared to ambulatory patients  
282 (**Supplemental Figs 6b and 6c, and Fig 7**). The median modified Z scores showed an overall higher

283 response in the hospitalized vs. ambulatory patients ( $p=0.03$ ), with higher median values observed in a  
284 constellation of cytokines/chemokines (e.g. IL-4, IL-7, IL-8, IL-13, IL-17A, IL-17E/IL-25, IL-18, IL-22,  
285 IL-27, MCP-3, M-CSF, MDC, MIG/CXCL9, MIP-1 $\alpha$ , MIP-1 $\beta$ , PDGF-AA, and TNF- $\beta$ ) (**Supplemental**  
286 **Fig 6b**). Correlation matrices of these cytokine/chemokine data further supported the notion of a stronger  
287 coordination of cytokine/chemokine alterations among the hospitalized patients as compared to the  
288 ambulatory patients whose correlation matrix was similar to that of the negative control (**Supplemental**  
289 **Fig 7**).

290 Comparison was also performed on individual cytokines or chemokines, and two cytokines were found to  
291 be significantly higher in hospitalized vs. ambulatory patients: IL-4 and IL-27 (**Fig 6b**). These were  
292 distinct from the 12 found to differ between COVID-19 positive and negative groups, and their levels did  
293 not significantly decline over 250 days post disease onset (slope=  $-0.0001$  and  $-0.0005$ , and  $p > 0.05$ ,  
294 **Supplemental Fig 5**). When we evaluated the subset of matched severe and mild specimens, only IL-27  
295 remained significantly higher in hospitalized vs. ambulatory patients with  $p$  value of 0.03 (**Fig 6c**).  
296 Therefore, the higher IL-27 levels between the hospitalized vs. ambulatory groups were evident in the  
297 plots of all COVID-19 patients (**Fig 7a**) and in the matched subset (**Fig 7b**). For comparison, two other  
298 cytokines were also plotted (**Fig 7c-f**). IL-4 was higher in sera of hospitalized vs. all ambulatory patients  
299 (**Fig 7c**) but showed inconsistent patterns in the matched subsets (**Fig 7d**). FGF-2, on the other hand, was  
300 comparable in hospitalized patients and all or matched ambulatory patients (**Fig 7e, f**). Notably, the IL-27  
301 levels correlated with IL-1 $\alpha$ , IL-3, IL-6 and TNF- $\alpha$  (Spearman  $r=0.61-0.75$  and  $p=0.01-0.03$ ) in the  
302 hospitalized patients, but not in the ambulatory patients (**Supplemental Fig 7**).

303

## 304 **Discussion**

305 This study examined serum Ab and cytokine/chemokine responses in SARS-CoV-2-infected patients with  
306 demographic risk factors for developing severe COVID-19, which included older age, male sex, and

307 Black/Hispanic racial or ethnic background. Most patients (81%), however, had mild disease requiring no  
308 hospitalization, and only ten were hospitalized. Comparison of the hospitalized vs. ambulatory patients  
309 within the cohort revealed comparable virus-specific Ab responses in terms of binding levels,  
310 neutralization titers, and Fc-mediated activities of ADCP and complement deposition. However, the S2-  
311 specific Ig responses were distinguishing in that anti-S2 Ab levels tended to increase in hospitalized  
312 patients and decrease in ambulatory patients over time, and correlated with all other Ab parameters tested  
313 more strongly among hospitalized patients than ambulatory patients. Furthermore, the overall cytokine  
314 responses in sera, which were collected from four days to >7 months post-disease onset, were elevated in  
315 the hospitalized vs. ambulatory patients. The IL-4 and IL-27 levels were notably higher in the hospitalized  
316 group and showed no apparent decline over the >7-month period. The greater levels of IL-27, but not IL-  
317 4, were maintained when the hospitalized patients were matched to subsets of ambulatory patients by  
318 absence or presence of comorbidities, early or late sample collection time, and spike-specific total Ig  
319 levels. Nonetheless, the importance of S2-specific Abs and IL-27 in contributing to and/or resulting from  
320 severe COVID-19 remains unclear and warrants further investigation.

321 IL-27 is a heterodimeric IL-12 family cytokine, consisting of IL-12p35-related p28 and Epstein-Barr  
322 virus-induced 3 (EBI3) proteins (40). Together with IL-12, IL-27 is an initiator of Th1 polarization of  
323 CD4<sup>+</sup> cells (41,42). IL-27 also promotes IFN- $\gamma$  production by CD8<sup>+</sup> T cells and NKT cells (43). Myeloid  
324 cell populations, including macrophages, inflammatory monocytes, microglia, and dendritic cells are the  
325 main sources of IL-27, which can be elicited by a range of microbial and immune stimuli (44). IL-27  
326 signaling in turn can induce the release of pro-inflammatory cytokines such as IL-1, TNF- $\alpha$ , IL-18, and  
327 IL-12 (45,46). Indeed, our data showed that IL-27 levels correlated with those of IL-1 $\alpha$  and TNF- $\alpha$  and  
328 that, with IL-27, IL-18 was elevated in hospitalized vs. ambulatory cases albeit without statistical  
329 significance. In a study looking at cytokine and leukocyte profile of 44 SARS-CoV-2-infected patients  
330 that were separated in two groups based on age (> or <60 years old), IL-27, together with CXCL8, IL-10,

331 IL-15 and TNF- $\alpha$ , was associated to older age, longer hospitalization, and more severe COVID-19 (29). In  
332 contrast, in a Singapore cohort, no difference was observed in IL-4 and IL-27 levels between symptomatic  
333 and asymptomatic patients; rather, higher levels of MCP-1 and PDGF-BB were detected in patients with  
334 persistent symptoms vs. symptom-free patients (47). Beyond COVID-19, the levels of IL-27 were found  
335 to increase in patients with pulmonary inflammatory diseases including tuberculosis, asthma, influenza,  
336 acute lung injury, lung cancer, chronic obstructive pulmonary disease, acute lung injury, acute respiratory  
337 distress syndrome, and community-acquired pneumonia (48–53), indicating that an elevated IL-27 level is  
338 likely a common response to lung infections and injuries.

339 In contrast to Th1-promoting IL-27, IL-4 is a cytokine that induces Th2 differentiation. Upon activation  
340 by IL-4, Th2 cells subsequently produce additional IL-4 in a positive feedback loop. IL-4 is produced  
341 primarily by mast cells, Th2 cells, eosinophils and basophils (54). IL-4, along with other Th2 cytokines, is  
342 involved in the airway inflammation observed in the lungs of patients with allergic asthma (55). In our  
343 COVID-19 cohort, IL-4 levels were higher when the hospitalized cases were compared with all  
344 ambulatory patients but not with matched ambulatory patients. Conflicting results also have been  
345 published regarding IL-4, which was either associated with severe COVID-19 (19), or was thought to be  
346 beneficial for the recovery of COVID-19 patients (56).

347 A constellation of elevated cytokines has been associated with severe cases of COVID-19. Here we  
348 observed higher median values for several cytokines in hospitalized vs. ambulatory groups, although only  
349 IL-27 was significantly elevated in hospitalized patients as compared to all and matched ambulatory  
350 patients. Interestingly, in the hospitalized patients but not in the ambulatory patients, the levels of IL-27  
351 correlated with those of IL-1 $\alpha$ , IL-3, IL-6 and TNF- $\alpha$ , which were previously reported to be elevated and  
352 correlated with severe COVID-19 (28,29,57,58). A study looking at serum IL-6, IL-8 and TNF- $\alpha$  at the  
353 time of hospitalization also found that they were strong and independent predictors of patient survival in a  
354 cohort of hospitalized patients (57). Yet, another study measuring IL-6 and IL-18 serum levels found IL-



355 18 to correlate with other inflammatory markers and reflect disease severity (59). And a different study  
356 looking at 48 cytokines, chemokines, and growth factors showed significantly higher IL-12 levels in the  
357 asymptomatic and mild disease groups than in the moderate and severe disease groups, while IL-4 levels  
358 were comparable and IL-27 was not examined (60). Nonetheless, these studies did not separate the  
359 individuals based on associated comorbidities, age, or racial/ethnic groups.

360 Limited information is available about cytokine responses among US minority groups, in particular  
361 African Americans and Hispanics who have higher rates of SARS-COV-2 infection, hospitalization, and  
362 death (30,61,62). African Americans are also more likely to have diabetes, hypertension, obesity, asthma,  
363 and heart disease, all of which are comorbidities associated with severe COVID-19. Moreover, little is  
364 known about cytokine levels in this population and in the context of associated comorbidities. The  
365 COVID-19-associated hospitalization rates are also higher among males than females (5.1 vs. 4.1 per  
366 100,000) (61). Indeed, markers of brain and endothelial injury and inflammation were shown to be sex  
367 specifically regulated in SARS-CoV-2 infection (63). Nonetheless, scant information is available  
368 regarding the differences/similarities in cytokine levels between males and females, even though sex  
369 differences are likely to impact immune responses to SARS-CoV-2, as seen against other viruses, for  
370 examples, sex hormone-regulated pDC responses and sex differences in cytokine and chemokine  
371 production and neutrophil recruitment during influenza virus infection (64).

372 In terms of Ab responses, the levels of anti-SARS-CoV-2 Abs, in particular IgA, and neutralization  
373 activities have been positively associated with COVID-19 severity (8–10). A longitudinal study of Italian  
374 patients presenting a wide range of clinical manifestations identified anti-S1 IgA as an indicator of  
375 COVID-19 severity (65). We performed Ig isotyping with the entire spike protein, precluding assessment  
376 of Ig isotypes against S1 and S2 subunits. In another study, faster induction of S2-reactive IgG during the  
377 first week of infection, along with IgG cross-reactivity with the common human beta coronaviruses ( $\beta$ -  
378 hCoVs), correlated with COVID-19 severity, implicating a biased early response toward S2 epitopes



379 cross-reactive with hCoVs (66). Comparison of spike proteins from SARS-CoV-2 (WA1) and hCoV  
380 strains shows varying levels of amino acid conservation across different spike regions. S1 and RBD  
381 exhibit only 25% to 30% identity, while S2 has higher percent identity: 41% to 42% with  $\beta$ -hCoVs (OC43  
382 and HKU1), and 34% with  $\alpha$ -hCoVs (229E and NL63). In our study, a distinguishable feature of Ab  
383 responses was the stronger concordance of Ig levels against S2 with anti-S1 Ig, anti-RBD Ig, and the other  
384 tested Ab parameters in the severe vs. ambulatory cases. These results suggest that the Ab responses to the  
385 S1 and S2 regions of spike were upregulated synchronously in the patients who went on to have severe  
386 COVID-19, but not in patients with mild cases. The S2-specific Ig responses were relatively low in both  
387 groups but tended to decline over time and disconnect from those of S1 in the ambulatory group. The S2  
388 epitopes targeted by Abs from severe vs. mild cases in our study have not been determined, but Abs  
389 against certain sites in the more conserved S2 subunit may play a role in preventing or promoting  
390 progression to severe COVID-19. Neutralizing mAbs against S2 have been reported, such as 3A3 specific  
391 for a conserved epitope in the hinge region between the heptad repeat-1 helix and the central helix (67)  
392 and B1 recognizing the beta-hairpin region (68), although the prevalence of these Abs in COVID-19  
393 patients is unknown. Garrido *et al.* demonstrated a correlation of IgG targeting different immunodominant  
394 conserved S2 regions with COVID-19 severity: Abs against heptad repeat-2 and S2' fusion peptide  
395 correlated with milder and more severe disease, respectively (69); the functional aspects of these anti-S2  
396 Abs are yet to be evaluated. Further studies also are warranted to focus on the activities of pre-existing and  
397 SARS-CoV-2-induced S2-specific Abs, including neutralization, Fab affinity, Fc glycosylation, and  
398 affinity for Fc receptors and complement, in patients with different disease severity and after COVID-19  
399 vaccination.

400 Fc-mediated Ab functions also have been associated with COVID-19 severity. Abs-mediated Fc $\gamma$ RIIa and  
401 Fc $\gamma$ RIIIa activation positively correlated with symptom severity among ambulatory New York patients at  
402 1-2 months post-disease onset (69). Additionally, IgG Fc glycome composition was shown to predict

403 disease severity, with patients with a poor outcome having, at diagnosis, IgG deficient in galactosylation  
404 and sialylation and more bis-GlcNAc structures (13). Since the Fc glycan composition influences Fc-  
405 mediated functions, further investigation may reveal distinct Fc activities. We previously observed higher  
406 complement-binding potency of SARS-CoV-2 spike-specific Abs elicited by vaccination vs. infection  
407 (35). In this study, comparable complement binding potencies were seen in spike-specific Abs from  
408 hospitalized vs. ambulatory COVID-19 patients. ADCP capacity was also similar, while other Fc activities  
409 such as antibody-dependent cellular cytotoxicity and affinity for the different Fc $\gamma$  receptors have not been  
410 studied.

411 The study was subject to additional limitations. The samples sizes were small, especially for the  
412 hospitalized patients, and this group included only survivors. Future study with larger sample sizes is  
413 needed to differentiate hospitalized patients requiring different levels of care and interventions and to  
414 match patient groups by race/ethnic groups and specific comorbidities. In addition, all samples were  
415 collected from patients during the first wave of infection in New York City in March-December 2020,  
416 when the initial SARS-CoV-2 variant was predominant and no vaccine or antiviral therapeutic  
417 intervention were available. It is unknown if the data presented herein can be extrapolated directly to  
418 responses against Delta, Omicron, and other variants emerging in the future. Vaccines and therapeutics  
419 now widely available would also impact Ab and cytokine/chemokine responses to infection. The antiviral  
420 functional assays were also limited to neutralization, ADCP, and complement binding, and to the  
421 evaluation of the original SARS-CoV-2 variant using recombinant protein or pseudovirus. Lastly, our  
422 study is primarily cross-sectional with samples from different subjects over a wide range of time points  
423 post-infection. Although minimal changes were apparent in the levels of antibodies and cytokines during  
424 the observation period, the individual responses at the early and late time points may differ and were not  
425 studied herein. The longitudinal samples tested for the initial nucleoprotein-IgG study were unavailable  
426 for the subsequent experiments.

427 In summary, among the older and mostly male VA patients studied, SARS-CoV-2-specific Ab levels and  
428 functional activities did not distinguish hospitalized and ambulatory COVID-19 cases. However, a  
429 discordant S2-specific Ab response was noted among the ambulatory patients. Moreover, higher levels of  
430 cytokines, notably IL-4 and IL-27, were induced and maintained in hospitalized vs. ambulatory cases.  
431 These data offer a pathway to pursue for a better understanding of the immune mechanisms that play a  
432 role in protection against vs. progression to severe COVID-19.

433

### 434 **Contributors**

435 J.K., S.Z-P., C.U., and C.E.H. wrote and edited the manuscript. J.K., C.E.H., and S.Z-P. designed the  
436 experiments. J.K. and G.S.L. performed the experiments and collected the data. J.K., G.S.L, A.N., C.U.  
437 and C.E.H. analyzed the data. K.Y.O., F.A., and B.L. provided protocols, antigens, cells, and pseudovirus  
438 stocks. V.S. and the PARIS study group provided banked human samples, J.C.B., R.E-G., and J.J.I.  
439 obtained specimens. All authors read and approved the final manuscript.

440

441 PARIS Study Team: Angela A. Amoako, Dalles Andre, Mahmoud H. Awawda, Katherine F. Beach, Maria  
442 C. Bermúdez-González, Rachel L Chernet, Emily D. Ferreri, Daniel L. Floda, Joshua Hamburger, Giulio  
443 Kleiner, Neko Lyttle, Wann A Mendez, Lubbertus CF Mulder, Ismail Nabeel, Kayla Russo, Ashley  
444 Beathrese T. Salimbangon, Miti Saksena, Levy A. Sominsky, Ania Wajnberg.

445

### 446 **Declaration of Interests**

447 The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2  
448 serological assays (U.S. Provisional Application Number 63/051,858, which list Viviana Simon as co-  
449 inventor.

450

### 451 **Source of funding statements**

452 This work was supported in part by the Department of Medicine of the Icahn School of Medicine at  
453 Mount Sinai Department of Medicine (to S.Z-P., C.E.H.); the Department of Microbiology and the Ward-  
454 Coleman estate for endowing the Ward-Coleman Chairs at the Icahn School of Medicine at Mount Sinai  
455 (to B.L.), the Department of Veterans Affairs [Merit Review Grant I01BX005794] (to C.E.H.) and  
456 [Research Career Scientist Award 1IK6BX004607] (to C.E.H.); the National Institutes of Health [grant  
457 AI139290] to C.E.H., [grants R01 AI123449, R21 AI1498033] to B.L., [grant R01 AI140909] to C.U.  
458 The PARIS cohort is funded by the NIAID Collaborative Influenza Vaccine Innovation Centers (CIVIC)  
459 contract 75N93019C00051 (PI: Dr. Krammer).

460

## 461 **Data sharing**

462 Final de-identified data sets underlying this publication will be shared upon written request.

463

## 464 **Acknowledgments**

465 We thank Dr. Florian Krammer for providing spike and RBD antigens, and all the study participants for  
466 their contribution to the research. We would like to thank the expertise and assistance of Dr. Christopher  
467 Bare and the Dean's Flow Cytometry CORE at Mount Sinai.

468

## 469 **References**

- 470 1. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease  
471 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for  
472 Disease Control and Prevention. *JAMA*. 2020 Apr 7;323(13):1239–42.
- 473 2. Yang R, Gui X, Xiong Y. Comparison of Clinical Characteristics of Patients with Asymptomatic  
474 vs Symptomatic Coronavirus Disease 2019 in Wuhan, China. *JAMA Netw Open*. 2020 May  
475 27;3(5):e2010182.
- 476 3. Aslan A, Aslan C, Zolbanin NM, Jafari R. Acute respiratory distress syndrome in COVID-19:  
477 possible mechanisms and therapeutic management. *Pneumonia*. 2021 Dec 6;13:14.
- 478 4. Chow N, Fleming-Dutra K, Gierke R, Hall A, Hughes M, Pilishvili T, et al. Preliminary Estimates  
479 of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease

- 480 2019 — United States, February 12–March 28, 2020. *Morb Mortal Wkly Rep*. 2020 Apr 3;69(13):382–6.
- 481 5. Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease Control  
482 and Prevention. [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases  
483 (COVID-19) in China]. *Zhonghua Liu Xing Bing Xue Za Zhi Zhonghua Liuxingbingxue Zazhi*. 2020 Feb  
484 10;41(2):145–51.
- 485 6. Sharma G, Volgman AS, Michos ED. Sex Differences in Mortality From COVID-19 Pandemic:  
486 Are Men Vulnerable and Women Protected? *JACC Case Rep*. 2020 Jul 15;2(9):1407–10.
- 487 7. COVID-19, Equity and Men’s Health | *International Journal of Mens Social and Community*  
488 *Health*. 2020 Jul 6 [cited 2022 Mar 29]; Available from:  
489 <http://ijmsch.com/index.php/IJMSCH/article/view/42>
- 490 8. Chvatal-Medina M, Mendez-Cortina Y, Patiño PJ, Velilla PA, Rugeles MT. Antibody Responses  
491 in COVID-19: A Review. *Front Immunol*. 2021 Apr 15;12:633184.
- 492 9. Ravichandran S, Lee Y, Grubbs G, Coyle EM, Klenow L, Akasaka O, et al. Longitudinal antibody  
493 repertoire in “mild” versus “severe” COVID-19 patients reveals immune markers associated with disease  
494 severity and resolution. *Sci Adv*. 2021 Mar;7(10):eabf2467.
- 495 10. Tang J, Ravichandran S, Lee Y, Grubbs G, Coyle EM, Klenow L, et al. Antibody affinity  
496 maturation and plasma IgA associate with clinical outcome in hospitalized COVID-19 patients. *Nat*  
497 *Commun*. 2021 Feb 22;12(1):1221.
- 498 11. Yang HS, Costa V, Racine-Brzostek SE, Acker KP, Yee J, Chen Z, et al. Association of Age With  
499 SARS-CoV-2 Antibody Response. *JAMA Netw Open*. 2021 Mar 22;4(3):e214302.
- 500 12. Takahashi T, Ellingson MK, Wong P, Israelow B, Lucas C, Klein J, et al. Sex differences in  
501 immune responses that underlie COVID-19 disease outcomes. *Nature*. 2020 Aug 26;1–9.
- 502 13. Vicente MM, Alves I, Gaifem J, Rodrigues CS, Fernandes Â, Dias AM, et al. Altered IgG  
503 glycosylation at COVID-19 diagnosis predicts disease severity. *Eur J Immunol* [Internet]. [cited 2022 Apr  
504 4];n/a(n/a). Available from: <https://onlinelibrary.wiley.com/doi/abs/10.1002/eji.202149491>
- 505 14. Lu-Culligan A, Chavan AR, Vijayakumar P, Irshaid L, Courchaine EM, Milano KM, et al.  
506 Maternal respiratory SARS-CoV-2 infection in pregnancy is associated with a robust inflammatory  
507 response at the maternal-fetal interface. *Med N Y N*. 2021 May 14;2(5):591-610.e10.
- 508 15. Arunachalam PS, Wimmers F, Mok CKP, Perera RAPM, Scott M, Hagan T, et al. Systems  
509 biological assessment of immunity to mild versus severe COVID-19 infection in humans. *Science*. 2020  
510 Sep 4;369(6508):1210–20.
- 511 16. Rizzi M, Costanzo M, Tonello S, Matino E, Casciaro FG, Croce A, et al. Prognostic Markers in  
512 Hospitalized COVID-19 Patients: The Role of IP-10 and C-Reactive Protein. *Dis Markers*.  
513 2022;2022:3528312.
- 514 17. Zhang X, Tan Y, Ling Y, Lu G, Liu F, Yi Z, et al. Viral and host factors related to the clinical  
515 outcome of COVID-19. *Nature*. 2020 Jul;583(7816):437–40.
- 516 18. Jing X, Xu M, Song D, Yue T, Wang Y, Zhang P, et al. Association between inflammatory  
517 cytokines and anti-SARS-CoV-2 antibodies in hospitalized patients with COVID-19. *Immun Ageing A*.  
518 2022 Mar 5;19(1):12.
- 519 19. Hu H, Pan H, Li R, He K, Zhang H, Liu L. Increased Circulating Cytokines Have a Role in  
520 COVID-19 Severity and Death With a More Pronounced Effect in Males: A Systematic Review and Meta-  
521 Analysis. *Front Pharmacol*. 2022;13:802228.
- 522 20. Walter LO, Cardoso CC, Santos-Pirath ÍM, Costa HZ, Gartner R, Werle I, et al. The relationship  
523 between peripheral immune response and disease severity in SARS-CoV-2-infected subjects: A cross-  
524 sectional study. *Immunology*. 2022 Apr;165(4):481–96.
- 525 21. Smieszek SP, Polymeropoulos VM, Polymeropoulos CM, Przychodzen BP, Birznieks G,  
526 Polymeropoulos MH. Elevated plasma levels of CXCL16 in severe COVID-19 patients. *Cytokine*. 2022  
527 Apr;152:155810.

- 528 22. Meffre E, Iwasaki A. Interferon deficiency can lead to severe COVID. *Nature*. 2020  
529 Nov;587(7834):374–6.
- 530 23. Zhang Q, Bastard P, Liu Z, Le Pen J, Moncada-Velez M, Chen J, et al. Inborn errors of type I IFN  
531 immunity in patients with life-threatening COVID-19. *Science*. 2020 Oct 23;370(6515):eabd4570.
- 532 24. Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann HH, Zhang Y, et al. Autoantibodies  
533 against type I IFNs in patients with life-threatening COVID-19. *Science*. 2020 Oct  
534 23;370(6515):eabd4585.
- 535 25. Ruetsch C, Brglez V, Crémoni M, Zorzi K, Fernandez C, Boyer-Suavet S, et al. Functional  
536 Exhaustion of Type I and II Interferons Production in Severe COVID-19 Patients. *Front Med*.  
537 2020;7:603961.
- 538 26. Dyavar SR, Singh R, Emani R, Pawar GP, Chaudhari VD, Podany AT, et al. Role of toll-like  
539 receptor 7/8 pathways in regulation of interferon response and inflammatory mediators during SARS-  
540 CoV2 infection and potential therapeutic options. *Biomed Pharmacother*. 2021 Sep;141:111794.
- 541 27. Ma A, Zhang L, Ye X, Chen J, Yu J, Zhuang L, et al. High Levels of Circulating IL-8 and Soluble  
542 IL-2R Are Associated With Prolonged Illness in Patients With Severe COVID-19. *Front Immunol*.  
543 2021;12:626235.
- 544 28. Ling L, Chen Z, Lui G, Wong CK, Wong WT, Ng RWY, et al. Longitudinal Cytokine Profile in  
545 Patients With Mild to Critical COVID-19. *Front Immunol*. 2021 Dec 6;12:763292.
- 546 29. Angioni R, Sánchez-Rodríguez R, Munari F, Bertoldi N, Arcidiacono D, Cavinato S, et al. Age-  
547 severity matched cytokine profiling reveals specific signatures in Covid-19 patients. *Cell Death Dis*. 2020  
548 Nov 6;11(11):957.
- 549 30. Rentsch CT, Kidwai-Khan F, Tate JP, Park LS, King JT, Skanderson M, et al. Patterns of COVID-  
550 19 testing and mortality by race and ethnicity among United States veterans: A nationwide cohort study.  
551 *PLoS Med*. 2020 Sep 22;17(9):e1003379.
- 552 31. Haralambieva IH, Salk HM, Lambert ND, Ovsyannikova IG, Kennedy RB, Warner ND, et al.  
553 Associations between race, sex and immune response variations to rubella vaccination in two independent  
554 cohorts. *Vaccine*. 2014 Apr 7;32(17):1946–53.
- 555 32. Amanat F, Stadlbauer D, Strohmeier S, Nguyen THO, Chromikova V, McMahon M, et al. A  
556 serological assay to detect SARS-CoV-2 seroconversion in humans. *Nat Med*. 2020 May 12;1–4.
- 557 33. Stadlbauer D, Amanat F, Chromikova V, Jiang K, Strohmeier S, Arunkumar GA, et al. SARS-  
558 CoV-2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and  
559 Test Setup. *Curr Protoc Microbiol*. 2020;57(1):e100.
- 560 34. Weiss S, Klingler J, Hioe C, Amanat F, Baine I, Kojic EM, et al. A High Through-put Assay for  
561 Circulating Antibodies Directed against the S Protein of Severe Acute Respiratory Syndrome Corona virus  
562 2. medRxiv. 2020 Apr 17;2020.04.14.20059501.
- 563 35. Klingler J, Lambert GS, Itri V, Liu S, Bandres JC, Enyindah-Asonye G, et al. Detection of  
564 Antibody Responses Against SARS-CoV-2 in Plasma and Saliva From Vaccinated and Infected  
565 Individuals. *Front Immunol*. 2021;12:759688.
- 566 36. Klingler J, Weiss S, Itri V, Liu X, Oguntuyo KY, Stevens C, et al. Role of IgM and IgA  
567 Antibodies in the Neutralization of SARS-CoV-2. *J Infect Dis*. 2020 Dec 24;
- 568 37. Oguntuyo KY, Stevens CS, Hung CT, Ikegame S, Acklin JA, Kowdle SS, et al. Quantifying  
569 absolute neutralization titers against SARS-CoV-2 by a standardized virus neutralization assay allows for  
570 cross-cohort comparisons of COVID-19 sera. medRxiv. 2020 Aug 15;2020.08.13.20157222.
- 571 38. Ikegame S, Siddiquey MNA, Hung CT, Haas G, Brambilla L, Oguntuyo KY, et al. Neutralizing  
572 activity of Sputnik V vaccine sera against SARS-CoV-2 variants. *Nat Commun*. 2021 Jul 26;12:4598.
- 573 39. Balasubramanian P, Williams C, Shapiro MB, Sinangil F, Higgins K, Nádas A, et al. Functional  
574 Antibody Response Against V1V2 and V3 of HIV gp120 in the VAX003 and VAX004 Vaccine Trials.  
575 *Sci Rep*. 2018 Jan 11;8(1):542.



- 576 40. Dokmeci E, Xu L, Robinson E, Golubets K, Bottomly K, Herrick CA. EBI3 deficiency leads to  
577 diminished T helper type 1 and increased T helper type 2 mediated airway inflammation. *Immunology*.  
578 2011 Apr;132(4):559–66.
- 579 41. Kastelein RA, Hunter CA, Cua DJ. Discovery and biology of IL-23 and IL-27: related but  
580 functionally distinct regulators of inflammation. *Annu Rev Immunol*. 2007;25:221–42.
- 581 42. Owaki T, Asakawa M, Morishima N, Hata K, Fukai F, Matsui M, et al. A role for IL-27 in early  
582 regulation of Th1 differentiation. *J Immunol Baltim Md 1950*. 2005 Aug 15;175(4):2191–200.
- 583 43. Carl JW, Bai XF. IL27: Its Roles in the Induction and Inhibition of Inflammation. *Int J Clin Exp*  
584 *Pathol*. 2008 Jan 1;1(2):117–23.
- 585 44. Yoshida H, Hunter CA. The immunobiology of interleukin-27. *Annu Rev Immunol*. 2015;33:417–  
586 43.
- 587 45. Wittmann M, Zeitvogel J, Wang D, Werfel T. IL-27 is expressed in chronic human eczematous  
588 skin lesions and stimulates human keratinocytes. *J Allergy Clin Immunol*. 2009 Jul;124(1):81–9.
- 589 46. Artis D, Villarino A, Silverman M, He W, Thornton EM, Mu S, et al. The IL-27 receptor (WSX-1)  
590 is an inhibitor of innate and adaptive elements of type 2 immunity. *J Immunol*. 2004 Nov 1;173(9):5626–  
591 34.
- 592 47. Ong SWX, Fong SW, Young BE, Chan YH, Lee B, Amrun SN, et al. Persistent Symptoms and  
593 Association With Inflammatory Cytokine Signatures in Recovered Coronavirus Disease 2019 Patients.  
594 *Open Forum Infect Dis*. 2021 Jun;8(6):ofab156.
- 595 48. Xu Z, Wang XM, Cao P, Zhang C, Feng CM, Zheng L, et al. Serum IL-27 predicts the severity  
596 and prognosis in patients with community-acquired pneumonia: a prospective cohort study. *Int J Med Sci*.  
597 2022 Jan 1;19(1):74–81.
- 598 49. Xu F, Liu Q, Lin S, Shen N, Yin Y, Cao J. IL-27 is elevated in acute lung injury and mediates  
599 inflammation. *J Clin Immunol*. 2013 Oct;33(7):1257–68.
- 600 50. Cao J, Zhang L, Li D, Xu F, Huang S, Xiang Y, et al. IL-27 is elevated in patients with COPD and  
601 patients with pulmonary TB and induces human bronchial epithelial cells to produce CXCL10. *Chest*.  
602 2012 Jan;141(1):121–30.
- 603 51. Su Y, Yao H, Wang H, Xu F, Li D, Li D, et al. IL-27 enhances innate immunity of human  
604 pulmonary fibroblasts and epithelial cells through upregulation of TLR4 expression. *Am J Physiol Lung*  
605 *Cell Mol Physiol*. 2016 Jan 15;310(2):L133-141.
- 606 52. Kosiński P, Wandtke T, Dyczek A, Wędrowska E, Roży A, Senderek T, et al. Increased levels of  
607 interleukin 27 in patients with early clinical stages of non-small cell lung cancer. *Pol Arch Intern Med*.  
608 2018 Feb 28;128(2):105–14.
- 609 53. Babadi AS, Kiani A, Mortaz E, Taghavi K, Khosravi A, Marjani M, et al. Serum Interleukin-27  
610 Level in Different Clinical Stages of Lung Cancer. *Open Access Maced J Med Sci*. 2019 Jan 15;7(1):45–  
611 9.
- 612 54. Gadani SP, Cronk JC, Norris GT, Kipnis J. Interleukin-4: A Cytokine to Remember. *J Immunol*  
613 *Baltim Md 1950*. 2012 Nov 1;189(9):4213–9.
- 614 55. Gour N, Wills-Karp M. IL-4 and IL-13 Signaling in Allergic Airway Disease. *Cytokine*. 2015  
615 Sep;75(1):68–78.
- 616 56. Wen W, Su W, Tang H, Le W, Zhang X, Zheng Y, et al. Immune cell profiling of COVID-19  
617 patients in the recovery stage by single-cell sequencing. *Cell Discov*. 2020 May 4;6:31.
- 618 57. Del Valle DM, Kim-Schulze S, Huang HH, Beckmann ND, Nirenberg S, Wang B, et al. An  
619 inflammatory cytokine signature predicts COVID-19 severity and survival. *Nat Med*. 2020 Aug 24;1–8.
- 620 58. Bénard A, Jacobsen A, Brunner M, Krautz C, Klösch B, Swierzy I, et al. Interleukin-3 is a  
621 predictive marker for severity and outcome during SARS-CoV-2 infections. *Nat Commun*. 2021 Feb  
622 18;12(1):1112.
- 623 59. Satış H, Özger HS, Aysert Yıldız P, Hızıl K, Gulbahar Ö, Erbaş G, et al. Prognostic value of

- 624 interleukin-18 and its association with other inflammatory markers and disease severity in COVID-19.  
625 Cytokine. 2021 Jan;137:155302.
- 626 60. Tjan LH, Furukawa K, Nagano T, Kiri T, Nishimura M, Arii J, et al. Early Differences in  
627 Cytokine Production by Severity of Coronavirus Disease 2019. *J Infect Dis*. 2021 Jan 7;223(7):1145–9.
- 628 61. Garg S, Kim L, Whitaker M, O’Halloran A, Cummings C, Holstein R, et al. Hospitalization Rates  
629 and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 -  
630 COVID-NET, 14 States, March 1-30, 2020. *MMWR Morb Mortal Wkly Rep*. 2020 Apr 17;69(15):458–  
631 64.
- 632 62. Alcendor DJ. Racial Disparities-Associated COVID-19 Mortality among Minority Populations in  
633 the US. *J Clin Med*. 2020 Jul 30;9(8):2442.
- 634 63. Savarraj J, Park E, Copo G, Hinds S, Morales D, Ahnstedt H, et al. Markers of brain and  
635 endothelial Injury and inflammation are acutely and sex specifically regulated in SARS-CoV-2 infection.  
636 In: medRxiv. 2021.
- 637 64. Scully EP, Haverfield J, Ursin RL, Tannenbaum C, Klein SL. Considering how biological sex  
638 impacts immune responses and COVID-19 outcomes. *Nat Rev Immunol*. 2020 Jul;20(7):442–7.
- 639 65. Siracusano G, Brombin C, Pastori C, Cugnata F, Noviello M, Tassi E, et al. Profiling Antibody  
640 Response Patterns in COVID-19: Spike S1-Reactive IgA Signature in the Evolution of SARS-CoV-2  
641 Infection. *Front Immunol* [Internet]. 2021 [cited 2022 Jun 8];12. Available from:  
642 <https://www.frontiersin.org/article/10.3389/fimmu.2021.772239>
- 643 66. Wang J, Li D, Cameron A, Zhou Q, Wiltse A, Nayak J, et al. IgG Against Human Betacoronavirus  
644 Spike Proteins Correlates With SARS-CoV-2 Anti-Spike IgG Responses and COVID-19 Disease  
645 Severity. *J Infect Dis*. 2022 Jan 29;jiac022.
- 646 67. Huang Y, Nguyen AW, Hsieh CL, Silva R, Olaluwoye OS, Wilen RE, et al. Identification of a  
647 conserved neutralizing epitope present on spike proteins from all highly pathogenic coronaviruses  
648 [Internet]. *bioRxiv*; 2021 [cited 2022 Jun 9]. p. 2021.01.31.428824. Available from:  
649 <https://www.biorxiv.org/content/10.1101/2021.01.31.428824v2>
- 650 68. Duan J, Yan X, Guo X, Cao W, Han W, Qi C, et al. A human SARS-CoV neutralizing antibody  
651 against epitope on S2 protein. *Biochem Biophys Res Commun*. 2005 Jul 22;333(1):186–93.
- 652 69. Garrido JL, Medina MA, Bravo F, McGee S, Fuentes-Villalobos F, Calvo M, et al. IgG targeting  
653 distinct seasonal coronavirus- conserved SARS-CoV-2 spike subdomains correlates with differential  
654 COVID-19 disease outcomes. *Cell Rep*. 2022 May 31;39(9):110904.
- 655

## 656 Figure legends

657 **Fig 1. Total Ig antibody responses to SARS-CoV-2 among hospitalized and ambulatory patients in the VA cohort.**

658 **a.** Demographic and clinical data of hospitalized (n = 10) vs. ambulatory (n = 42) patients.

659 **b.** IgG responses to nucleoprotein in hospitalized and ambulatory patients with or without comorbidities.

660 The dotted line represents the cut-off at 1.4.

661 **c.** Total Ig levels against spike and nucleoprotein in hospitalized (n = 10) vs. ambulatory (n = 42) patients.

662 AUC: area under the curve. The red line represents the median. The dotted line represents the cut-off, calculated as  
663 mean + 3SD of 5 COVID-19-negative specimens.

664 **d.** Total Ig levels against spike and nucleoprotein between patients with (n = 24) vs without (n = 28) comorbidities.



665 The red line represents the median. The dotted line represents the cut-off, calculated as mean + 3SD of 5 COVID-19-  
666 negative specimens.

667 e. Changes of spike-specific total Ig levels over time post-symptom onset.

668 The dotted lines represent the linear regression 95% confidence bands.

669 f. Changes of S2-specific total Ig levels over time post-symptom onset in hospitalized (n = 10, left) vs. ambulatory (n = 42,  
670 right) patients.

671 The dotted lines represent the linear regression 95% confidence bands.

672 **Fig 2. Neutralization activities against SARS-CoV-2 among hospitalized and ambulatory patients in the VA cohort.**

673 a. Neutralization titers in sera of ambulatory (n = 42) vs. hospitalized (n = 10) patients.

674 The red line represents the median. Negative is set at 10, the lowest reciprocal dilution.

675 b. Neutralization titers in sera of patients with (n = 24) vs. without (n = 31) comorbidities.

676 The red line represents the median. Negative is set at 10, the lowest reciprocal dilution.

677 c. Spearman correlation between neutralization titers and age of patients.

678 d. Changes in neutralization titers over time post-symptom onset.

679 The dotted lines represent the linear regression 95% confidence bands.

680 **Fig 3. Antibody isotypes against SARS-CoV-2 in sera of matched hospitalized vs. ambulatory VA patients.**

681 The levels of spike-specific IgM, IgG1-4, IgA1 and IgA2 were measured in sera from matched hospitalized vs. ambulatory  
682 patients.

683 The data are represented as mean fluorescent intensity (MFI) at a 1:200 serum dilution, each sample was tested in duplicate.

684 The dotted line represents the cut-off.

685 Statistical significance was calculated by a Wilcoxon matched-pairs test; each hospitalized patient was compared to 2 or 3  
686 matched ambulatory patients.

687 **Fig 4. Fab-mediated neutralization and Fc-mediated activities of SARS-CoV-2-specific antibodies in sera from matched  
688 hospitalized and ambulatory VA patients.**

689 a. Neutralization activities in matched hospitalized vs. ambulatory patients. IC<sub>50</sub>: reciprocal serum titers yielding 50%  
690 neutralization.

691 b. Spike-specific ADCP activities in matched hospitalized vs. ambulatory patients.

692 c. C1q binding to spike-specific antibodies in matched hospitalized vs. ambulatory patients.

693 d. C3d binding to spike-specific antibodies in matched hospitalized vs. ambulatory patients.

694 AUC: area under the titration curve.

695 Statistical significance was calculated by a Wilcoxon matched-pairs test: six specimens from hospitalized patients were

696 compared to the average of 2 or 3 matched specimens from ambulatory patients.

697 ns: not significant ( $p > 0.05$ ).

698 **Fig 5. Correlations of binding and functional Ab levels in matched hospitalized and ambulatory VA patients.**

699 Spearman correlation matrix of serum Ab binding levels and functional activities were generated to compare matched (a)

700 hospitalized (n = 6) vs. (b) ambulatory (n = 14) patients.

701 **Fig 6. Differential cytokine/chemokine responses among hospitalized vs. ambulatory VA patients.**

702 Statistically different responses in infected vs. negative individuals (a), hospitalized vs. ambulatory patients (b) and matched

703 hospitalized vs. ambulatory patients (c) were indicated by color codes.

704 Statistical significance was calculated by unpaired (a, b) or paired (c) non-parametric t-test. Significance was similarly

705 achieved with other tests (parametric t-test and non-parametric Mann Whitney Wilcoxon in R).

706 **Fig 7. Cytokines responses among hospitalized and ambulatory VA patients.**

707 Data from three cytokines (IL-27, IL-4, and FGF-2) are presented as examples to show similarities and differences between

708 hospitalized vs. all ambulatory patients (a, c, e) or between matched hospitalized vs. ambulatory patients (b, d, f). Statistical

709 significance was calculated in GraphPad Prism by unpaired (a, c, e) or paired (b, d, f) non-parametric t-test (\*:  $p < 0.05$ , \*\*:  $p < 0.01$ , ns:  $p > 0.05$ ).

710 Significance was similarly achieved with parametric t-test and non-parametric Mann Whitney Wilcoxon in

711 R.

712 **Supplemental Fig 1. Total Ig antibody responses to SARS-CoV-2 among hospitalized and ambulatory VA patients.**

713 a. Total Ig levels against RBD, S1 and S2 in hospitalized (n = 10) vs. ambulatory (n = 42) patients.

714 AUC: area under the titration curve. The red line represents the median. The dotted line represents the cut-off, calculated as

715 mean + 3SD of 5 COVID-19-negative specimens.

716 b. Total Ig levels against RBD, S1 and S2 between patients with (n = 24) vs. without (n = 28) comorbidities.

717 The red line represents the median. The dotted line represents the cut-off, calculated as mean + 3SD of 5 COVID-19-negative

718 specimens.

719 c. Changes of RBD-, S1-, S2-, and nucleoprotein-specific total Ig levels over time post-symptom onset.

720 The dotted lines represent the linear regression 95% confidence bands.

721 **Supplemental Fig 2. RBD-specific antibody isotypes in sera of matched hospitalized and ambulatory VA patients.**

722 RBD-specific IgM, IgG1-4, IgA1 and IgA2 levels were measured in sera from matched hospitalized vs. ambulatory patients.

723 The data are presented as mean fluorescent intensity (MFI) at a 1:200 serum dilution. Each sample was tested in duplicate. The  
724 dotted line represents the cut-off.

725 Statistical significance was calculated by a Wilcoxon matched-pairs test; each hospitalized patient was compared to 2 or 3  
726 matched ambulatory patients.

727 **Supplemental Fig 3. Fc-mediated activities of RBD-specific antibodies in sera from matched hospitalized and**  
728 **ambulatory VA patients.**

729 **a.** C1q binding to RBD-specific antibodies in matched hospitalized vs. ambulatory patients.

730 **b.** C3b binding to RBD-specific antibodies in matched hospitalized vs. ambulatory patients.

731 AUC: area under the titration curve. Statistical significance was calculated by a Wilcoxon matched-pairs test: each hospitalized  
732 patient was compared to 2 or 3 matched specimens from ambulatory patients.

733 **Supplemental Fig 4. Differential cytokine/chemokine responses in sera of COVID-19-positive vs. -negative VA patients.**

734 Forty-eight cytokines and chemokines were measured in serum specimens from COVID-19-positive (n = 52) vs. negative (n =  
735 28).

736 Data are shown as concentration in pg/mL (log<sub>10</sub>). Red line represents median. Highlighted red boxes show cytokines or  
737 chemokines with significant differences (\*: p<0.05, \*\*: p<0.01, \*\*\*: p<0.001, \*\*\*\*: p<0.0001), calculated by unpaired non-  
738 parametric t-test (GraphPad Prism). Significance was similarly achieved with parametric t-test and non-parametric Mann  
739 Whitney Wilcoxon in R.

740 **Supplemental Fig 5. Levels of cytokines and chemokines in sera of COVID-19 VA patients over time.**

741 Changes of pg/mL concentrations of 11 cytokines (shown in Fig 5 to be statistically different between COVID-19-positive and  
742 -negative individuals) + IL-4 and IL-27 over time post-symptom onset.

743 The dotted lines represent the linear regression 95% confidence bands.

744 **Supplemental Fig 6. Differences in the levels of cytokines and chemokines among hospitalized and ambulatory VA**  
745 **patients.**

746 The levels of cytokines/chemokines were measured in sera from hospitalized (n = 10) vs. ambulatory (n = 42) patients.

747 **a.** The data are shown as pg/mL concentration in log<sub>10</sub>. The gray line represents the median. The highlighted red boxes show  
748 the cytokines with significant differences between two patient groups (\*: p<0.05, \*\*: p<0.01), calculated by unpaired non-  
749 parametric t-test (GraphPad Prism). Significance was similarly achieved with parametric t-test and non-parametric Mann  
750 Whitney Wilcoxon in R.

751 **b.** The data are shown as median modified Z scores. p value was obtained from one-side t test comparing median values of all

752 cytokines/chemokines in hospitalized vs. ambulatory groups.

753 **Supplemental Fig 7. Correlations of cytokines and chemokines in hospitalized, ambulatory, and control patients.**

754 Spearman correlation matrix of serum cytokines/chemokines levels were generated to compare hospitalized patients (n = 10),


755 ambulatory patients (n = 42), and COVID-19-negative individuals (n = 28).

# Figure 1


(a)

	Hospitalized n = 10	Ambulatory n = 42	Mann-Whitney test
<b>Age</b> Median (IQR)	68 (49-74)	62 (54-74)	p = 0.66 (ns)
<b>Sample collection</b> Median days post-onset (IQR)	178 (65-191)	188 (29-215)	p = 0.35 (ns)
<b>% Male</b>	100%	76%	
<b>% White</b>	40%	48%	
<b>% Black and/or Hispanic</b>	80%	83%	
<b>% Black</b>	50%	52%	
<b>% Hispanic</b>	40%	43%	
<b>% Subjects with comorbidity</b>	40%	48%	


(b)




(c)





(d)



(e)




(f)




# Figure 2


(a)




(b)




(c)



(d)



# Figure 3











# Figure 5

## (a)

### Total Ig

### Isotyping

### Functions







## (b)

### Total Ig

### Isotyping

### Functions



# Figure 6

(a)

All Infected vs Negative	
sCD40L	<0.0001
EGF	
Eotaxin	
FGF-2	0.002
FLT-3L	
Fractalkine	
G-CSF	
GM-CSF	
GRO $\alpha$	
IFN- $\alpha$ 2	0.003
IFN $\gamma$	
IL-1 $\alpha$	0.005
IL-1 $\beta$	
IL-1RA	0.0003
IL-2	
IL-3	0.04
IL-4	
IL-5	
IL-6	
IL-7	
IL-8	
IL-9	
IL-10	
IL-12p40	
IL-12p70	
IL-13	
IL-15	0.004
IL-17A	0.02
IL-17E/IL-25	<0.0001
IL-17F	
IL-18	
IL-22	
IL-27	
IP-10	
MCP-1	
MCP-3	
M-CSF	0.02
MDC	0.008
MIG/CXCL9	
MIP-1 $\alpha$	
MIP-1 $\beta$	
PDGF-AA	
PDGF-AB/BB	
RANTES	<0.0001
TGF $\alpha$	
TNF $\alpha$	
TNF $\beta$	
VEGF-A	

(b)

All Hospitalized vs Ambulatory	
sCD40L	
EGF	
Eotaxin	
FGF-2	
FLT-3L	
Fractalkine	
G-CSF	
GM-CSF	
GRO $\alpha$	
IFN- $\alpha$ 2	
IFN $\gamma$	
IL-1 $\alpha$	
IL-1 $\beta$	
IL-1RA	
IL-2	
IL-3	
IL-4	0.002
IL-5	
IL-6	
IL-7	
IL-8	
IL-9	
IL-10	
IL-12p40	
IL-12p70	
IL-13	
IL-15	
IL-17A	
IL-17E/IL-25	
IL-17F	
IL-18	
IL-22	
IL-27	0.02
IP-10	
MCP-1	
MCP-3	
M-CSF	
MDC	
MIG/CXCL9	
MIP-1 $\alpha$	
MIP-1 $\beta$	
PDGF-AA	
PDGF-AB/BB	
RANTES	
TGF $\alpha$	
TNF $\alpha$	
TNF $\beta$	
VEGF-A	







(c)

Matched Hospitalized vs Ambulatory	
sCD40L	
EGF	
Eotaxin	
FGF-2	
FLT-3L	
Fractalkine	
G-CSF	
GM-CSF	
GRO $\alpha$	
IFN- $\alpha$ 2	
IFN $\gamma$	
IL-1 $\alpha$	
IL-1 $\beta$	
IL-1RA	
IL-2	
IL-3	
IL-4	
IL-5	
IL-6	
IL-7	
IL-8	
IL-9	
IL-10	
IL-12p40	
IL-12p70	
IL-13	
IL-15	
IL-17A	
IL-17E/IL-25	
IL-17F	
IL-18	
IL-22	
IL-27	0.03
IP-10	
MCP-1	
MCP-3	
M-CSF	
MDC	
MIG/CXCL9	
MIP-1 $\alpha$	
MIP-1 $\beta$	
PDGF-AA	
PDGF-AB/BB	
RANTES	
TGF $\alpha$	
TNF $\alpha$	
TNF $\beta$	
VEGF-A	

Higher, p<0.0001	Lower, p<0.0001
Higher, p<0.001	Lower, p<0.001
Higher, p<0.01	Lower, p<0.01
Higher, p<0.05	Lower, p<0.05
ns	ns

# Figure 7

Log10(concentration in pg/mL)



All specimens

Matched specimens